We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · August 26, 2021

Liraglutide Reduces Cardiac Adipose Tissue in Type 2 Diabetes

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Liraglutide Reduces Cardiac Adipose Tissue in Type 2 Diabetes: A Secondary Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
Diabetes Obes Metab 2021 Aug 13;[EPub Ahead of Print], IKB Rasmussen, EH Zobel, RS Ripa, BJ von Scholten, VR Curovic, JK Jensen, A Kjaer, TW Hansen, P Rossing

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.